Related Experiment Video

Updated: Aug 23, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Effect of drugs in secondary disease progression in patients with multiple sclerosis

Ludwig Kappos1

  • 1Departments of Neurology and Research, University Hospitals, Kantonsspital, Petersgraben 4, CH-4031 Basel, Switzerland. lkappos@uhbs.ch

Multiple Sclerosis (Houndmills, Basingstoke, England)
|June 29, 2004
PubMed

Insights

Interferon beta (IFN beta) shows potential in slowing secondary progressive multiple sclerosis (SPMS) progression and improving quality of life. While one trial showed significant effects on disability, all studies noted benefits in relapse rates and MRI markers.

Area of Science:

  • Neuroimmunology
  • Clinical Neurology
  • Translational Medicine

Background:

  • Secondary progressive multiple sclerosis (SPMS) is characterized by relentless worsening disability.
  • Limited ambulation is a common outcome for most SPMS patients.
  • Existing treatments aim to modulate the immune system.

Purpose of the Study:

  • To evaluate the efficacy of interferon beta (IFN beta) in treating SPMS.
  • To assess the impact of IFN beta on disease progression and relapse rates.
  • To review current immunomodulatory and immunosuppressive therapies for SPMS.

Main Methods:

  • Analysis of four major clinical trials: EUSPMS, SPECTRIMS, NASPMS, and IMPACT.
  • Assessment of disease progression using the Expanded Disability Status Scale (EDSS).
  • Evaluation of treatment effects on relapse frequency, T2 lesion load, and gadolinium-enhancing lesions.

Main Results:

  • One trial (EUSPMS) demonstrated a significant positive effect of IFN beta on EDSS.
  • All trials showed significant benefits of IFN beta on relapse rates, T2 lesion load, and gadolinium enhancement.
  • Immunosuppressants like Mitoxantrone show positive effects but carry controversial risk-benefit profiles.

Conclusions:

  • Interferon beta (IFN beta) therapy can significantly slow disease progression and enhance quality of life in SPMS patients.
  • While IFN beta demonstrates benefits, new strategies targeting neurodegeneration are crucial.
  • Current treatment options for SPMS, including immunosuppressants, require careful risk-benefit consideration.

More Related Videos

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...